ACADIA Pharmaceuticals Inc

2026. g. 28. aug. 20:07 UTC

ACADIA Pharmaceuticals received EU approval for DAYBU to treat Rett syndrome. Shares are declining despite this development, reflecting unusual volatility during Friday's session.

2026. g. 27. aug. 23:41 UTC

ACADIA Pharmaceuticals shares are trading lower in after-market hours, despite being above the 20-day moving average and near the upper end of its trading range.

2026. g. 26. aug. 20:08 UTC

ACADIA Pharmaceuticals is trading lower amid a weaker market following inflation data that may influence future Federal Reserve policy decisions.

2026. g. 25. aug. 20:07 UTC

Analysts' upgrades boost ACADIA Pharmaceuticals, with Deutsche Bank raising its price target to $38 and Citigroup to $40 following DAYBUE's EU approval.

2026. g. 24. aug. 20:06 UTC

ACADIA Pharmaceuticals received European Commission approval for DAYBU, the first treatment for Rett syndrome in the EU. Shares are advancing during Monday's session.

2026. g. 21. aug. 19:56 UTC

ACADIA Pharmaceuticals shares are higher, recovering from an early dip. The move aligns with broader market trends following a surge in Bitcoin prices.

2026. g. 20. aug. 20:01 UTC

ACADIA Pharmaceuticals shares are lower amid a broader decline in biotechnology stocks, with unusual volatility noted today and cumulative returns down since Wednesday.

2026. g. 19. aug. 19:46 UTC

ACADIA Pharmaceuticals is trading higher, reflecting positive sentiment in the biotechnology sector amid declining bond yields and increased liquidity, despite a recent pullback.

2026. g. 18. aug. 20:02 UTC

BMO maintained an Outperform rating on ACADIA Pharmaceuticals with a $36 price target, contributing to positive market sentiment and advancing shares today.

2026. g. 17. aug. 23:06 UTC

ACADIA Pharmaceuticals shares are trading higher in after-market hours, maintaining a gain while above their 20-day moving average and near a one-month high.

2026. g. 13. aug. 20:01 UTC

ACADIA Pharmaceuticals Inc shares are lower today, continuing a decline from Wednesday's close. No specific news was identified to explain the movement.

2026. g. 12. aug. 19:56 UTC

Needham maintained its Buy rating on ACADIA Pharmaceuticals and raised the price target to $41. Shares are trading higher since Tuesday's close.

2026. g. 11. aug. 19:36 UTC

ACADIA Pharmaceuticals remains near unchanged amid broader market sentiment influenced by geopolitical tensions and upcoming U.S. inflation reports affecting interest rate policy.

2026. g. 7. aug. 20:06 UTC

ACADIA Pharmaceuticals Inc shares are advancing, maintaining a strong position above the 20-day moving average and near the upper end of their one-month range.

2026. g. 6. aug. 23:41 UTC

ACADIA Pharmaceuticals shares are higher in after-market trading, reflecting strong performance above its 20-day moving average and nearing the upper end of its one-month range.

2026. g. 5. aug. 20:02 UTC

ACADIA Pharmaceuticals shares rise following strong Q2 results and positive analyst ratings, with revenue guidance increased to $1.24 billion to $1.30 billion.

2026. g. 4. aug. 23:01 UTC

Acadia Pharmaceuticals shares are higher after reporting strong Q2 results, with GAAP net sales of DAYBUE reaching $125 million and raising full-year revenue guidance.

2026. g. 3. aug. 21:01 UTC

ACADIA Pharmaceuticals Inc shares are lower in after-market trading, continuing a trend of three consecutive sessions finishing lower without any specific news identified.

2026. g. 31. jūl. 20:03 UTC

ACADIA Pharmaceuticals shares are lower today, continuing a decline since Thursday's close. Rising Treasury yields and crude oil prices contribute to inflation concerns.

2026. g. 30. jūl. 19:58 UTC

ACADIA Pharmaceuticals shares are higher, reflecting a broader recovery in tech stocks amid improving market sentiment and bargain hunting after recent sell-offs.

2026. g. 29. jūl. 20:41 UTC

ACADIA Pharmaceuticals shares are lower in after-market trading amid a broader market decline linked to rising crude oil prices and geopolitical tensions.

2026. g. 28. jūl. 20:06 UTC

ACADIA Pharmaceuticals is rising amid strong performance in the Biotechnology sector. The stock is nearing the upper end of its one-month range.

2026. g. 27. jūl. 20:01 UTC

ACADIA Pharmaceuticals Inc. shares are higher today, continuing an upward trend since Friday's close, despite no specific news driving the price movement.

2026. g. 24. jūl. 19:56 UTC

ACADIA Pharmaceuticals shares are higher since Thursday's close, despite a dip earlier in the session. The stock remains below its 20-day moving average.

2026. g. 23. jūl. 10:06 UTC

ACADIA Pharmaceuticals is trading higher in pre-market hours, recovering from an earlier dip. The stock remains below its 20-day moving average.

2026. g. 22. jūl. 22:16 UTC

ACADIA Pharmaceuticals shares are lower in after-market trading, with unusual activity noted. Broader market concerns may be influencing investor sentiment.

2026. g. 21. jūl. 23:16 UTC

ACADIA Pharmaceuticals Inc. shares traded roughly flat in after-market hours, remaining near the upper end of their one-month trading range.

2026. g. 20. jūl. 19:56 UTC

Acadia Pharmaceuticals received Fast Track designation for remlifanserin, but shares are lower today, continuing a trend of declines over the past three sessions.